A non-invasive liquid biopsy resolves the diagnostic blind spot in chronic kidney disease

Chronic kidney disease is a serious global health burden, and its early detection is critical for slowing progression to kidney failure. Current diagnostic tests rely on blood markers that are distorted by muscle mass and urine tests that often miss structural damage without protein leakage. Researchers developed a non-invasive liquid biopsy that measures a specific protein marker, MUC1, on urinary extracellular vesicles to accurately assess renal parenchymal integrity. This method bypasses the systemic metabolic noise of traditional blood tests and provides a stable, person-specific functional signature. Longitudinal analysis showed that the difference between this novel urine-based test and standard blood tests reveals hidden kidney injury and successfully predicts rapid functional decline. This non-invasive method using a single urine sample enables comprehensive assessment of tubular and glomerular integrity and represents a new tool for early disease detection.